Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C and Inherited Bleeding Disorders

Author(s):
Shahin MeratShahin Merat1, Amir Ali SohrabpourAmir Ali Sohrabpour1, Siamak KhaleghiSiamak Khaleghi1, Masoud Reza SohrabiMasoud Reza Sohrabi1, Katayon Samimi RadKatayon Samimi Rad1, Amir Reza RadmardAmir Reza Radmard1, Reza MalekzadehReza Malekzadeh2,*
1Digestive Disease Research Center, Tehran University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), Tehran, IR.Iran
2Digestive Disease Research Center, Tehran University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), [email protected], Tehran, IR.Iran

Hepatitis Monthly:Vol. 4, issue 7; 59-64
Published online:Sep 30, 2004
Article type:Research Article
How to Cite:Merat S, Sohrabpour A, Khaleghi S, Sohrabi M, Rad K, et al. Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C and Inherited Bleeding Disorders. Hepat Mon. 2004;4(7):. doi:

Abstract

Full Text

Full text is available in PDF

Similar Articles

30
Sep
2004

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Mohammad Reza Zali,
Hamid Mohaghegh Shalmani,
Mohsen Norouzinia,
Amir Hooshang MohammadAlizadeh,
Azita Nowroozi,
Negar Behrouz

Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:

30
Sep
2004

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani,
Babak Haghpanah,
Ali Reza Sayyah,
Ali Asad Hashtroudi,
Mohammad Bashashati,
Parisa Poursamimi
,et al.

Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:

1
Jan
2015

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari

Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955

30
Sep
2004

The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia

Shahram Mirmomen,
Naser Ebrahimi Daryani,
Reza Malekzadeh,
Mohammad Reza Zali,
Babak Haghpanah,
Parisa Poursamimi
,et al.

Mirmomen S, Daryani N, Malekzadeh R, Zali M, Haghpanah B, et al. The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia. Hepat Mon. 2004;4(7):. doi:

30
Sep
2004

Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Seyed Moayed Alavian,
Behzad Hajarizadeh,
Bashir Hajibeigi,
Taher Doroudi,
Amir Kambiz Hamadanizadeh,
Koroush Abar

Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:

Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles